In a post hoc analysis of 611 ATTRibute-CM participants, acoramidis was associated with a 41% lower risk of first outpatient worsening heart failure than placebo over 30 months.
In a post hoc analysis of 611 ATTRibute-CM participants, acoramidis was associated with a 41% lower risk of first outpatient worsening heart failure than placebo over 30 months.
In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...
In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...
In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...
Researchers created a mouse model of osteoglophonic dysplasia to better understand why the condition causes excess FGF23, low phosphate levels, and abnormal bone development.
Researchers created a mouse model of osteoglophonic dysplasia to better understand why the condition causes excess FGF23, low phosphate levels, and abnormal bone development.
